drugset / Trial / NCT07024030
Safety and Efficacy Trial of a Targeted PSMA Fluorescent Contrast Agent (DGPR1008) for Intraoperative Imaging of Prostate Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
a single-arm, open-label, multi-center study to evaluate safety, tolerability, pharmacokinetics, and the effectiveness of near-infrared fluorescence imaging during surgery.
Timeline
- Start
- 2024-10-30
- Primary completion
- 2024-12-31
- Completion
- 2025-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DGPR1008 | Diagnostic / imaging agent | 0.02 mg/kg | Intravenous |
| Subject | DGPR1008 | Diagnostic / imaging agent | 0.04 mg/kg | Intravenous |
Indications
No indication recorded.